TREATMENTS FOR EGFR MUTATION-POSITIVE (M plus ) NSCLC PATIENTS - A NETWORK META-ANALYSIS (NMA) BY MUTATION TYPE

被引：6
|
作者：
Popat, S. [1 ]
Yang, J. C. H. [2 ]
Lungershausen, J. [3 ]
Griebsch, I [3 ]
Marten, A. [4 ]
Wu, Y. L. [5 ]
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Natl Taiwan Univ, Taipei 10764, Taiwan
[3] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2166
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A615 / A615
页数：1
相关论文
共 50 条
  • [41] Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
    Pan, Jie
    Cai, Xiaoping
    Cao, Zhuo
    Pan, Jiongwei
    Zheng, Hao
    PHARMACOLOGY, 2023, 108 (01) : 8 - 16
  • [42] Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
    Sung, Mike R.
    Tomasini, Pascale
    Le, Lisa W.
    Kamel-Reid, Suzanne
    Tsao, Ming-Sound
    Liu, Geoffrey
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Li, Janice J. N.
    Feld, Ronald
    Leighl, Natasha B.
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (02):
  • [43] Efficacy and Tolerability Analysis of Icotinib in EGFR Mutation-Positive and Unknown Advanced NSCLC Patients from Eastern Coastal China
    Zhang, Chuantao
    Xu, Xiaomei
    Wang, Xiaofei
    Hou, Helei
    Yan, Chun
    Yu, Wenjun
    Tan, Airong
    Lin, Congmin
    Cheng, Xiaofeng
    Yu, Zijun
    Liu, Junshuai
    Liu, Xin
    Zhang, Xiaochun
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S524 - S524
  • [44] Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC
    Santos, Edgardo
    Kaplan, Barry
    Kirshner, Eli
    Croft, Elisabeth
    Sequist, Lecia
    Burke, Lea
    Munley, Jiefen
    Oxnard, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1237 - S1237
  • [45] Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A RealWorld Study
    Yan, N. N.
    Guo, S.
    Huang, S.
    Zhang, H.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S622 - S622
  • [46] Afatinib in EGFR Mutation-Positive NSCLC: Activity in Patients with Brain Metastases, and Impact on CNS Progression/Spread
    O'Byrne, K.
    Yang, J. C.
    Wu, Y.
    Hirsh, V.
    Yamamoto, N.
    Popat, S.
    Tamiya, A.
    Maerten, A.
    Schuler, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S855 - S855
  • [47] Afatinib in patients with EGFR mutation-positive (EGFRm plus ) NSCLC harbouring uncommon mutations: Experience in 'Real-World' clinical practice
    Maerten, Angela
    Brueckl, Wolfgang
    Laack, Eckhart
    Hoffmann, Christopher
    Zhou, Caicun
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 160
  • [48] Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Major Uncommon Mutations
    Yang, J. Chih-Hsin
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S31 - S31
  • [49] Randomized, Double-Blind Study of Erlotinib Plus Ramucirumab or Placebo in First Line for Patients with EGFR Mutation-Positive Metastatic NSCLC
    Polit, R. R.
    Reck, M.
    Juan Vidal, O.
    Nadal, E.
    Lee, P.
    Alexandris, E.
    He, S.
    Nakagawa, K.
    Garon, E. B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1577 - S1577
  • [50] Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC
    James E. Frampton
    Targeted Oncology, 2022, 17 : 369 - 376
12345